Decoding China's Health Insurance & National Reimbursement Drug List (NRDL)
[Tuesday , 16th May 2023]
Decoding China's Health Insurance & National Reimbursement Drug List (NRDL)
Grace Wang
REACH24H Consulting Group China
If you have any question about this webinar, please contact us:
+86 (0)571 8710 3829

China’s health insurance and National Reimbursement Drug List (NRDL) are significant for innovative drug products to reach the market in hospitals. Reimbursement makes innovative drugs, usually at high prices, to be more affordable to patients.

For pharmaceutical companies, earning a place in the NRDL is an approach to widen market access for their drug products. But does NRDL listing a guarantee of sales growth? What is the role of NRDL, a list of drugs adjusted almost annually, in the market dynamics? This webinar organized by ChemLinked BaiPharm Portal is going to answer the questions.


1. China’s Health Insurance System

1.1 Source of Money for Reimbursement

1.2 Places for Selling Drugs Eligible for Reimbursement

1.3 Limitations for Reimbursement

1.4 Reimbursement Scope and Rate 

2. China’s National Reimbursement Drug List (NRDL)

2.1 NRDL Chronology

2.2 Current NRDL

2.3 Highlights in 2022 NRDL Adjustment

2.4 NRDL’s Influence on Market

2.5 How to Get Products Listed on NRDL?

2.6 How Do Hospitals Purchase NRDL-listed Drugs?

2.7 Is NRDL Listing Worthwhile?

Related Article

- China Adds 111 Drugs to 2022 National Reimbursement Drug List

- Biogen's SMA Drug Spinraza Gets Access to More Patients in China Due to NRDL

- China Promotes Distribution of Medicare-covered Drugs Through Dual Channel

Grace Wang
ChemLinked Regulatory Analyst / Editor
Grace Wang is a regulatory analyst and editor specializing in China's pharmaceutical regulations and market trends. She provides articles and webinars to help overseas pharma companies enter the Chinese market. Her areas of focus include DMF filing, NDA, ANDA, pharmacovigilance, health insurance, and volume-based procurement (VBP).